HomepageGRFS • NASDAQ
add
Grifols
Vorige slotkoers
$Â 9,32
Dag-range
$Â 9,42 - $Â 9,54
Jaar-range
$Â 6,19 - $Â 11,14
Beurswaarde
8,40Â mld. USD
Gem. volume
533,38K
Koers/winst
18,71
Dividendrendement
1,86%
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(EUR) | jun 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,89Â mld. | 4,03% |
Bedrijfskosten | 394,25Â mln. | -5,69% |
Netto inkomsten | 117,06Â mln. | 688,78% |
Netto winstmarge | 6,19 | 654,88% |
Winst per aandeel | 0,19 | 36,36% |
EBITDA | 414,24Â mln. | 13,12% |
Effectief belastingtarief | 27,36% | — |
Balans
Totale activa
Totale passiva
(EUR) | jun 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 582,38Â mln. | -74,23% |
Totale activa | 19,77Â mld. | -11,32% |
Totale passiva | 12,17Â mld. | -13,05% |
Totaal aandelenvermogen | 7,60 mld. | — |
Uitstaande aandelen | 680,51 mln. | — |
Koers-boekwaardeverhouding | 1,23 | — |
Rendement op activa | 4,29% | — |
Rendement op kapitaal | 4,91% | — |
Kasstroom
Nettomutatie in liquide middelen
(EUR) | jun 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 117,06Â mln. | 688,78% |
Operationele kasstroom | 155,27Â mln. | -38,60% |
Kasstroom uit beleggingen | -107,65Â mln. | -107,98% |
Kasstroom uit financiering | -181,41Â mln. | -405,19% |
Nettomutatie in liquide middelen | -194,12Â mln. | -111,66% |
Vrije kasstroom | 67,94Â mln. | -95,81% |
Over
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Opgericht
18 nov 1940
Website
Werknemers
23.800